McKesson Stock May Rise With PRISM Vision Holdings Acquisition
MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.
MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment?
McKesson's third-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
McKesson (MCK) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, McKesson (MCK) stood at $594.75, denoting a -1.63% change from the preceding trading day.
Gear Up for McKesson (MCK) Q3 Earnings: Wall Street Estimates for Key Metrics
Evaluate the expected performance of McKesson (MCK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Stock Drops Despite Market Gains: Important Facts to Note
McKesson (MCK) closed at $602.95 in the latest trading session, marking a -0.24% move from the prior day.
McKesson (MCK) Stock Declines While Market Improves: Some Information for Investors
McKesson (MCK) closed at $586.08 in the latest trading session, marking a -1.1% move from the prior day.
Wall Street Analysts Think McKesson (MCK) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
MCK Stock Gains 4% in 3 Weeks: Should You Buy, Hold or Sell?
McKesson MCK has started 2025 on a positive note, with the stock climbing 4% so far in January as investors remain optimistic about the company's performance in 2025. MCK's growth this year will be driven by its strategic focus on oncology and biopharma services, supported by the expansion of The US Oncology Network and the launch of InspiroGene for cell and gene therapies.
Here's Why McKesson (MCK) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Value Investors Buy McKesson (MCK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
